Articles
Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). What is STS-01? STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting…
Read More
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…
Read More
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read More
Follicle Thought is pleased to present a recent interview we conducted with Geoff Hamilton, the CEO of Stemson Therapeutics. Stemson Therapeutics is a biotech company founded in 2018 that aims to revolutionize hair regrowth through stem cell technology. So, let’s get into the interview. FT: Hi Geoff, Thank you for coming back to Follicle Thought…
Read More
This week, there is interesting news for those with alopecia areata. Nektar Therapeutics has announced that it will launch a Phase 2b trial for its drug rezpegaldesleukin (REZPEG), which will be assessed in individuals suffering from severe to very severe alopecia areata (AA). Nektar Therapeutics is a biotech firm with several indications in the pipeline…
Read More
Pelage Pharma Presents Data From its Phase 1 Clinical Study: Update (03/09/2024) On March 9th, Pelage Pharma unveiled data at the AAD 2024 Annual Meeting, showcasing PP405. Through translational and Phase 1 clinical studies, PP405 demonstrated its ability to reactivate dormant hair follicle stem cells, triggering hair regrowth. Pelage Pharma has provided an overview of…
Read More
Earlier this month, Stemson Therapeutics announced its hair follicle regeneration research advancement. What is Stemson Therapeutics Working On? The company is focused on developing a cell therapy solution for hair loss. They use autologous (meaning from the self) induced pluripotent stem cells (iPSCs) to engineer follicular units to form new hair follicles. These will be…
Read More
We interviewed skin and hair biology researcher Xunwei Wu about his ongoing research in hair follicle regeneration. Let’s look at what researchers are working on for the future of hair regrowth. Who is Xunwei Wu? Xunwei Wu is a researcher who has worked in dermatology (specifically skin biology) for more than 20 years. In the…
Read More
A team of researchers led by Chunming Wang from the University of Macau, in collaboration with scientists from the University of Nanjing and Wenzhou Medical University, have conducted a study on the use of an oligosaccharide biomaterial (OG6) to stimulate hair growth in mice. The study is based on understanding the crucial role of local…
Read More
Interesting news from Technoderma Medicines Inc. about their Phase 2a trial. TDM-105795: Positive Results Observed Compared to Baseline Technoderma Medicines Inc. has completed a Phase 2a clinical trial for TDM-105795, “A Randomized, Double-Blind, Vehicle Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia.” TDM-105795 is…
Read More